ETH-LAD

ETH-LAD is a psychedelic drug similar to LSD. Research has shown formation of ETH-LAD from incubated in human serum, suggesting that it functions as a prodrug.  1P-ETH-LAD is part of the lysergamide chemical class. Similar to ETH-LAD, 1P-ETH-LAD has been reported to be significantly more potent than LSD itself, and is reported to largely mimic ETH-LAD’s psychedelic effects.
The use 1P-ETH-LAD for human consumption is hightly advised against, since there are little documentation about it’s long term effects but also on dosage.

What was it all about?

ETH-LAD has similar properties as lysergic acid diethylamide (LSD). These properties have fascinated scientists regarding 1P-ETH-LAD, across disciplines and the exploration of other analogues and derivatives has been motivated by deepening the understanding of ligand-receptor interactions at the molecular level of 1P-ETH-LAD, as well as by the search for new therapeutics .

Several 1P-ETH-LAD congeners have appeared on the new psychoactive substances (NPS) market in the form of blotters or powders. Examples include 1-propionyl-LSD (1P–LSD), AL-LAD, and LSZ. The absence of analytical data for novel compounds is a frequent challenge encountered in clinical and toxicological investigations.

Two newly emerging lysergamides, namely N⁶-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1P–ETH-LAD, were characterized by gas chromatography–mass spectrometry (GC–MS), low and high mass accuracy electrospray MS(/MS), GC solid-state infrared analysis, high performance liquid chromatography diode array detection as well as nuclear magnetic resonance spectroscopy. Limited analytical data for ETH-LAD were previously available, whereas information about 1P–ETH-LAD has not previously been encountered in the scientific literature.

What effect could it give

The “body high” of 1P-ETH-LAD can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, it is a little less sharp in its tingles, less likely to be uncomfortable but otherwise essentially identical.

How is ETH-LAD related to lysergamides?

Lysergamides are amides of lysergic acid.

Ergoline refers to a class of compounds derived from alkaloids of a group of fungi known as ergot in the claviceps genus. These compounds typically have strong psychedelic effects.

The most popular and well known Lysergamides and their properties are listed in following easy to read table:

Compound	RN1	RN2	R1	R6	Structure
1B-LSD	CH2CH3	CH2CH3	C=OCH2CH2CH3	CH3
1P-ETH-LAD	CH2CH3	CH2CH3	C=OCH2CH3	CH2CH3
1P-LSD	CH2CH3	CH2CH3	C=OCH2CH3	CH3
1cP-LSD	CH2CH3	CH2CH3	C=OC3H5	CH3
ALD-52	CH2CH3	CH2CH3	C=OCH3	CH3
AL-LAD	CH2CH3	CH2CH3	H	CH2CH=CH2
Ergotamine	*	H	H	CH3
ETH-LAD	CH2CH3	CH2CH3	H	CH2CH3
LAE-32	CH2CH3	H	H	CH3
LSA	H	H	H	CH3
LSH	CH2(OH)CH3	H	H	CH3
LSD	CH2CH3	CH2CH3	H	CH3
iso-LSD	CH2CH3	CH2CH3	H	CH3
LSM-775	CH2CH2O-	CH2CH2–	H	CH3
LSZ	CH(CH3)CH2–	CH(CH3)CH2–	H	CH3
MiPLA	CH(CH3)2	CH3	H	CH3
EiPLA	CH(CH3)2	CH2CH3	H	CH3
PARGY-LAD	CH2CH3	CH2CH3	H	CH2C≡CH
PRO-LAD	CH2CH3	CH2CH3	H	CH2CH2CH3

ETH-LAD  where does it come from, and who “designed” it?

Biochemist Alexander Shulgin accidentally discovered MDMA, the  most famous and infamous party drugs of the 80’s and 90’s.

It was back in 1976, in his backyard laboratory. As tradition, he tried it out on himself. 1P-ETH-LAD “First awareness at 35 minutes,” he wrote in his journal of the mood-altering drug, “smooth and it was very nice.” He felt it held therapeutic promise.

Alexander Shulgin, 88, died Monday at his home in Lafayette, Calif., according to an announcement on his website. He had been diagnosed earlier this year with liver cancer.

The patent was such a boon to Dow that the company gave Shulgin wide discretion as to what he wanted to research.

“Dow said, ‘Do as you wish,’ ” Shulgin said in a 2002 interview with the Independent newspaper in London. “So I did. I did 1P-ETH-LAD”

Shulgin had been introduced to psychedelics when he tried mescaline with friends in 1960. It was a life-changing experience, unearthing long-forgotten incidents and feelings.

But Shulgin had little interest in the recreational use of 1P-ETH-LAD. “Use them with respect as to the transformations they can achieve, and you have an extraordinary research tool,” Shulgin wrote. “Go banging about with a psychedelic drug for a Saturday night turn-on, and you can get into a really bad place.”

Shulgin was born June 17, 1925, in Berkeley to parents who were both schoolteachers. He was admitted to Harvard in 1942 on a full scholarship, but he hated it.

“The people around me were sons and daughters of important people, with money and property, position and stature,” he told the Independent. “I was not, and there was no social blending at all.”

For many years, the government mostly left Shulgin and his backyard lab alone, perhaps in part because he analyzed possible contraband for the federal Drug Enforcement Administration.

After trying MDMA and 1P-ETH-LAD, Shulgin gave samples to therapists. Some reported highly positive results, but the feelings of warmth and euphoria that it engendered made it a natural for the party scene and labs around the world with no connection to Shulgin started turning it out.

Reports of Ecstasy being taken in clubs and outdoor mega-parties became rampant, followed by accounts of bad reactions. Supporters of the serious use of MDMA as well as 1P-ETH-LAD countered that the negative reports were highly exaggerated, and that street versions of what was supposed to be Ecstasy often contained little if any MDMA.

But the public outcry against Ecstasy was strong. In 1986, the DEA put MDMA on its Schedule 1 list of dangerous drugs with “a high potential for abuse.”

In 1993, the DEA dramatically ended its relationship with Shulgin, raiding his lab and seizing some of his drugs found there. He was fined $25,000.

Over time, restrictions on research were lifted. There are ongoing studies of how the drug can aid in post-traumatic stress disorder therapy, and a current study at Harbor-UCLA Medical Center is looking into how it can ease social anxiety in high-functioning adults with autism.

Doblin’s goal is to make 1P-ETH-LAD and MDMA an approved prescription drug by 2021.